This guideline presents recommendations for the diagnosis and management of patients with celiac disease. Celiac disease is an immune-based reaction to dietary gluten (storage protein for wheat, barley, and rye) that primarily affects the small intestine in those with a genetic predisposition and resolves with exclusion of gluten from the diet. There has been a substantial increase in the prevalence of celiac disease over the last 50 years and an increase in the rate of diagnosis in the last 10 years. Celiac disease can present with many symptoms, including typical gastrointestinal symptoms (e.g., diarrhea, steatorrhea, weight loss, bloating, fl atulence, abdominal pain) and also non-gastrointestinal abnormalities (e.g., abnormal liver function tests, iron defi ciency anemia, bone disease, skin disorders, and many other protean manifestations). Indeed, many individuals with celiac disease may have no symptoms at all. Celiac disease is usually detected by serologic testing of celiac-specifi c antibodies. The diagnosis is confi rmed by duodenal mucosal biopsies. Both serology and biopsy should be performed on a glutencontaining diet. The treatment for celiac disease is primarily a gluten-free diet (GFD), which requires signifi cant patient education, motivation, and follow-up. Non-responsive celiac disease occurs frequently, particularly in those diagnosed in adulthood. Persistent or recurring symptoms should lead to a review of the patient ' s original diagnosis to exclude alternative diagnoses, a review of the GFD to ensure there is no obvious gluten contamination, and serologic testing to confi rm adherence with the GFD. In addition, evaluation for disorders associated with celiac disease that could cause persistent symptoms, such as microscopic colitis, pancreatic exocrine dysfunction, and complications of celiac disease, such as enteropathy-associated lymphoma or refractory celiac disease, should be entertained. Newer therapeutic modalities are being studied in clinical trials, but are not yet approved for use in practice. Given the incomplete response of many patients to a GFD-free diet as well as the diffi culty of adherence to the GFD over the long term, development of new effective therapies for symptom control and reversal of infl ammation and organ damage are needed. The prevalence of celiac disease is increasing worldwide and many patients with celiac disease remain undiagnosed, highlighting the need for improved strategies in the future for the optimal detection of patients. Am J Gastroenterol 2013; 108:656-676; doi: 10.1038/ajg.2013 
INTRODUCTION
Th is clinical guideline addresses the diagnosis, treatment, and overall management of patients with celiac disease (CD), including an approach to the evaluation of non-responsive CD. While it is primarily directed at the care of adult patients, variations pertinent to the pediatric population have been included. Each section will provide specifi c recommendations based on the current literature and a summary of the evidence supporting those recommendations. Th e GRADE system was used to evaluate the quality of supporting evidence ( 1 ) ( Table 1 ) . A " strong " recommendation is made when the benefi ts clearly outweigh the negatives and the result of no action. " Conditional " is used when some uncertainty remains about the balance of benefi t / potential harm. Th e quality of the evidence is graded from high to low. " High " -quality evidence indicates that further research is unlikely to change the authors ' confi dence in the estimate of eff ect. " Moderate " -quality evidence indicates that further research would be likely to have an impact on the confidence of the estimate, whereas " Low " -quality evidence indicates that further study would likely have an important impact on the confi dence in the estimate of the eff ect and would likely change the estimate. Summary of the evidence . CD is one of the most common causes of chronic malabsorption ( 2 ) . Th is results from injury to the small intestine with loss of absorptive surface area, reduction of digestive enzymes, and consequential impaired absorption of micronutrients such as fat-soluble vitamins, iron, and potentially B 12 and folic acid ( 3 ) . In addition, the infl ammation exacerbates symptoms of malabsorption by causing net secretion of fl uid that can result in diarrhea. Th e failure of absorption of adequate calories leads to weight loss, and the malabsorption results in abdominal pain and bloating ( 3 ) . Th ese are common symptoms associated with CD ( 4, 5 ) . CD remains underdiagnosed in the United States ( 6 ) . CD may present in many ways ( 7 ) . Currently, active case-fi nding (serologic testing for CD in patients with symptoms or conditions closely associated with CD) is the favored strategy to increase detection of CD ( 8 ) . Active case-fi nding may increase detection of CD among patients with symptoms attending a primary-care offi ce, although this strategy is insuffi cient to detect most patients with CD ( 7 ) . Th ere is no consensus regarding which symptoms, laboratory abnormalities, and / or associated diseases require evaluation for CD. Th e frequency of CD in common clinical scenarios varies from modestly elevated, such as irritable bowel syndrome, to substantially elevated, such as unexplained iron-defi ciency anemia ( Table 2 ) ( 9 -11 ) .
Th e complexity of deciding who to test is exemplifi ed by patients with dyspepsia. Th e prevalence of biopsy-proven CD in patients with dyspepsia is 1 % , similar to that of the general population ( 12 ) , and therefore systematic screening for CD is not recommended based on disease prevalence alone. However, treatment for dyspepsia can be a clinical challenge ( 13 ) and dyspepsia as a symptom of CD will readily respond to the gluten-free diet (GFD) ( 4, 14 ) . Th us, mucosal biopsies of the duodenum should be considered in patients with dyspepsia who undergo investigation with upper endoscopy because of persistent symptoms despite initial therapy, are aged > 55 years old, and / or present alarm symptoms (e.g., weight loss or clinical evidence of anemia) ( 15 ) .
Th e frequency of CD is substantially increased in patients who have a fi rst-degree family member aff ected with CD ( 16, 17 ) . Th e precise risk is highest in monozygous twins, next in human leukocyte antigen (HLA)-matched siblings, siblings, and fi nally parents and children of patients with CD ( 16 ) . A lower rate probably applies to second-degree relatives ( 18 ) . Members of families who have more than one individual already identifi ed with CD are at higher risk of CD and recommendations for screening should extend to all other family members, including second-degree relatives ( 19 ) . Th e estimates of prevalence of CD in family members 
Decrease grade if
• Serious ( − 1) or very serious ( − 2) limitation to study quality
• Important inconsistency ( − 1)
• Some ( − 1) or major ( − 2) uncertainty about directness
• Imprecise or sparse data ( − 1)
• High probability of reporting bias ( − 1)
Increase grade if
• Strong evidence of association -signifi cant relative risk of > 2 ( < 0.5) based on consistent evidence from two or more observational studies, with no plausible confounders ( + 1)
• Very strong evidence of association -signifi cant relative risk of > 5 ( < 0.2) based on direct evidence with no major threats to validity ( + 2)
• Evidence of a dose -response gradient ( + 1)
• All plausible confounders would have reduced the effect ( + 1)
Defi nition of grades of evidence
• High=Further research is unlikely to change our confi dence in the estimate of effect
• Moderate=Further research is likely to have an important impact on our confi dence in the estimate of effect and may change the estimate
• Low=Further research is very likely to have an important impact on our confi dence in the estimate of effect and is likely to change the estimate
• Very low=Any estimate of effect is very uncertain
Reprinted with permission from Camilleri et al. ( 264 ) .
vary substantially, with one large multicenter study in the United States showing a rate as low as 5 % in both fi rst-and seconddegree relatives ( 18 ) . Other studies, especially those that are community-based, show a rate that is substantially higher, aff ecting up to 20 % in siblings and 10 % in other fi rst-degree relatives ( 16 ) . Th e clinical implications are that newly diagnosed patients with CD should inform their fi rst-degree family members of the potential increased risk for CD and the recommendation for testing. In addition, health-care providers should determine whether there is a family history of CD in patients with symptoms or signs suggestive of CD and if so consider screening the patient. Testing of truly symptomless fi rst-degree relatives is reasonable but controversial. Even those patients who initially thought themselves to be without symptoms on direct questioning at the time of detection oft en report improved health aft er adapting to the GFD because of disappearance of symptoms that may not have been previously explained ( 20 ) . Others may have symptoms that they did not consider abnormal until aft er they initiated a GFD and these symptoms resolve ( 21 ) . Asymptomatic patients detected by screening do not experience new symptoms aft er onset of a GFD ( 22 ) . Th e majority of patients with CD identifi ed on the basis of screening reported dietary adherence and improvements in quality of life on the GFD ( 20 ) . A small proportion of patients, however, reported increased health-related anxiety aft er diagnosis ( 23 ) . Overall satisfaction with the diagnosis was high (93 % ) ( 20 ) .
Abnormal liver blood tests, in particular elevations of alanine aminotransferase and aspartate aminotransferase, are commonly seen in clinical care, although the prevalence of clinically significant liver disease is low ( 24 ) . In CD, hypertransaminasemia is oft en a subclinical fi nding that is gluten dependent ( 25 ) . Patients with unexplained elevation of liver enzymes should be assessed for CD ( 26 ) . Th ere are reasonable data to show that glutendependent hypertransaminasemia will normalize in most patients ( > 95 % ) on a GFD ( 27 ) . Rarely, CD can be associated with severe liver disease ( 28, 29 ) .
Th ere is evidence that CD is substantially more common in patients with Type I DM than in the general Caucasian population. Th e estimates vary between 3 and 10 % ( 30 -32 ) . In children, it has been suggested that yearly or every-other-year screening for CD be undertaken utilizing serology. Patients with Type I DM who are undergoing upper endoscopy should undergo duodenal biopsies to rule out CD if they have never been tested previously.
Aft er gastrointestinal symptoms, the second most common manifestation of CD in patients with Type I DM is diminished or impaired bone mineralization. Th ere is some evidence suggesting that there is added disease burden to patients already struggling with the management of Type I DM. In addition, there is good evidence that gastrointestinal symptoms present at diagnosis will respond to a GFD with overall improvement in quality of life related to GI symptoms. Th e impact of the treatment of CD on the management of Type I DM is mixed ( 33 ) . Some data suggest an increase in absorption, leading to the need for increased insulin doses. Other data suggest improvement of DM controlled by reduction of hypoglycemic events, especially postprandial.
Testing for CD in asymptomatic patients with Type I DM is controversial. No signifi cant adverse outcomes were identifi ed in children with Type 1 DM identifi ed by screening who delay therapy with a GFD for up to 2 years ( 34 ). However, it is necessary to look at the potential long-term impact of CD in Type I DM as well ( 35 ) . A large study from Sweden showed an increased risk of diabetic retinopathy in patients with coexistent Type I DM and CD ( 36 ) . Patients with undiagnosed CD and Type 1 DM had a higher prevalence of retinopathy (58 % vs. 25 % ) and nephropathy (42 % vs. 4 % ) ( 37 ) . Treatment with a GFD for 1 year was safe in patients with coexistent Type I DM and CD ( 37 ) . Th e eff ect (if any) of a GFD on DM-related complications requires further investigation.
Parents of children with Type 1 DM or the children of parents with Type 1 DM are at increased risk of CD, estimated to be ~ 4 % ( 38 -40 ) . Because many patients with unrecognized CD may actually have symptoms that improve on a GFD, informing such parents of the risk of CD is suggested. Also, a family history of either CD or Type 1 DM indicates an increased risk of CD in the patient and CD should be considered. Th ere are no data to support a recommendation about when to stop screening for CD in children with Type 1 DM, but screening is not necessary in the absence of HLA-DQ2 and -DQ8. Summary of the evidence . Th e use of TTG-IgA testing and its accuracy in the primary-care setting and referral cohorts has been extensively studied ( 9 ) . Th e sensitivity of the TTG-IgA for untreated CD is about 95 % ( 41 ). Th e specifi city is also 95 % or greater. Th e higher the titer of the test, the greater the likelihood of a true positive result ( 9 ) . Th e test is most commonly based on an enzyme-linked immunosorbent assay test and less commonly on radioimmunoassay ( 42 ) . Th ere are recognized diff erences in test performance between the various commercially available test kits, but overall there is consistency in the sensitivity and specifi city of the test ( 42 -44 ) .
In the past, several antibody tests have been developed to detect CD ( 45 ) . Antibodies may be directed against native or altered cereal derived peptides. Anti-gliadin antibodies (AGA) have been used for decades and are reasonably accurate when there is a high pretest prevalence of CD ( 46 ) . However, it was with the advent of auto-antibodies, fi rst directed against reticulin, then endomysium antibodies (EMA), and fi nally TTG antibodies, that the truly celiac-specifi c testing was developed ( 47 ) . Th e identifi cation of TTG IgA antibody as the target antigen for IgA EMA antibodies was a major advance ( 48 ) . Th is antigen was initially produced by extraction from the liver or purifi cation from human red cells and, most recently, by recombinant protein production. TTGbased assays have brought accurate serology for CD into the reach of most doctors and hospitals. Th e College of American Pathology laboratory profi ciency survey has included TTG antibody testing for several years and most laboratories in the United States that provide TTG testing participate. Other similar systems are in place outside the United States.
IgA defi ciency is more common in CD than in the general population. It aff ects anywhere between 1 in 400 to 1 in 800 members of the general population, but occurs in 2 -3 % of patients with CD and 1 % of those getting tested for CD ( 49, 50 ) . In patients in whom there is a high pre-test prevalence of CD, the measurement of IgA levels should be considered, especially if IgA-based celiac serology test is negative. One approach is to measure total IgA at the beginning of testing to determine whether IgA levels are suffi cient and, if not, to incorporate IgG-based testing into the serology testing cascade. DGPs IgG and / or TTG IgG would then be the preferred test in this circumstance ( 51, 52 ) . EMA IgG is not widely available. It has been suggested that IgA defi ciency should be considered if the TTG-IgA levels are undetectable ( 53, 54 ) . However, not all assays can detect this with any accuracy or the result is merely reported as negative. While there are limited data on the sensitivity of each of these tests for CD in an IgA-defi cient person, this may be about 80 -90 % individually and higher if the tests are combined. If the suspicion for CD is high, intestinal biopsy should be pursued even when serologies are negative. Finding IgA defi ciency should prompt evaluation for other diseases that may cause villous atrophy, such as giardiasis, small-bowel bacterial overgrowth, or common variable immunodefi ciency ( 55 ) .
Th e antibodies directed against gliadin or its deamidated products as well as the self-antigen TTG are dependent on the ingestion of gluten. Th e reduction or cessation of dietary gluten leads to a decrease in the levels of all these celiac-associated antibodies to normal concentrations. While little is known about the precise dynamics of the reduction, a weakly positive individual may become negative within weeks of strict adherence to GFD ( 56 ) . Aft er 6 -12 months of adhering to a GFD, 80 % of subjects will test negative by serology ( 57 ) . By 5 years, more than 90 % of those adhering to the GFD will have negative serologies ( 58 ) .
While antibodies directed against native gliadin (AGA) have been in use for several decades, there is a wide variability in their diagnostic accuracy ( 43 ) . Both IgA and IgG AGA have sensitivities and specifi cities inferior to those of the TTG-IgA and DGPIgA assays ( 57 ) and should no longer be included in the routine testing strategy for CD.
No one test for CD has a perfect sensitivity or specifi city. Th us, individual tests may be combined in commercially available panels. Th is strategy may increase the sensitivity if any positive test is regarded as an overall positive result; however, the increased sensitivity comes at the expense of a reduction of specifi city ( 59 ) . Unless all patients who test positive in the panel undergo histological confi rmation of CD, this practice may lead to incorrect Summary of the evidence . Gastrointestinal symptoms alone cannot accurately diff erentiate CD from other common gastrointestinal disorders (e.g., 20 -50 % of patients with CD fulfi lled the Rome criteria for irritable bowel syndrome) ( 4, 67 ) . A metaanalysis showed a pooled prevalence of irritable bowel syndrometype symptoms of 38 % (95 % confi dence interval (CI), 27 -50 % ) in patients with CD ( 68 ) . Improvement of gastrointestinal symptoms or clinical exacerbation aft er re-introduction of gluten has a very low PPV for CD (36 % and 28 % , respectively) and should not be used for diagnosis in the absence of other supportive evidence ( 69 ) . Moreover, ingestion of gluten can cause gastrointestinal symptoms including abdominal pain and bloating in the absence of CD ( 70 ) . A GFD improved gastrointestinal symptoms in about 60 % of patients with diarrhea-predominant irritable bowel syndrome, especially those with HLA-DQ2 ( 71 ) . A positive CD-specifi c serology (TTG, DGP, and EMA) in patients with villous atrophy confi rms the diagnosis of CD ( 43 ) . TTG-IgA may be negative in 5 -16 % of patients with biopsy-confi rmed CD tested when following a gluten-containing diet ( 41, 57 ) . IgA EMA-negative CD has been described in patients with normal IgA ( 72 ) . Th us, a negative CD-specifi c serology in patients with villous atrophy does not completely exclude the diagnosis of CD though it does make it much less likely. Other causes of villous atrophy are summarized in Table 3 .
Histological response to GFD in patients with villous atrophy strongly supports a diagnosis of CD. HLA typing and histological response may help to rule out or confi rm the diagnosis of CD in patients with sero-negative CD ( 73,74 ). and over diagnosis followed by unnecessary treatment with GFD. Conversely, if the threshold is set that all tests within the panel must be positive for a " positive " panel test, then the specifi city and hence positive predictive value (PPV) for CD will be increased, but at the expense of sensitivity ( 9 ) . One diagnostic approach is shown in Figure 1 .
Th ere is some evidence that both TTG and EMA are less sensitive in young children (less than 2 years of age) ( 60, 61 ) . In this age group the sensitivity of AGA and DGP antibodies is higher than both the TTG and EMA ( 61 -63 ) . In general, AGA have a low sensitivity and specifi city and are not recommended as a screening test for CD ( 64, 65 ) . Although DGP tests perform less well than TTG and EMA tests, they are superior to the AGA ( 66 ) . For this reason it is preferable to combine the TTG with DGP tests when screening young children.
CONFIRMATORY TESTING IN CD

Recommendations
(1) Th e confi rmation of a diagnosis of CD should be based on a combination of fi ndings from the medical history, physical examination, serology, and upper endoscopy with histological analysis of multiple biopsies of the duodenum. Small-intestinal biopsy has been central to the confi rmation of the diagnosis of CD since the late 50s ( 75 ) . Traditionally, the diagnosis of CD required three intestinal biopsies: a biopsy on a gluten-containing diet (diagnosis), a biopsy aft er a period on GFD, and a biopsy aft er a gluten challenge ( 76 ) . Subsequent studies demonstrated that a biopsy at the time of diagnosis in children without subsequent intestinal biopsies was able to correctly diagnose 95 % of cases ( 77 ) . Th e availability of CD-specifi c serological tests facilitated the recognition of many CD patients and the wide spectrum of clinical manifestations ( 6, 18 ) . A positive serological test is supportive of the diagnosis but no single test is 100 % specifi c for CD and the diagnostic accuracy varies dramatically between laboratories ( 43 ). Indeed, a large international study found that laboratory sensitivity ranged from 63 to 93 % and specifi city ranged from 96 to 100 % when comparing TTG assays among various research and clinical laboratories ( 42 ) . Serological tests may perform less well in the clinical setting than research (a positive result of both TTG and EMA had a sensitivity of 81 % ) ( 78 ) .
A diagnosis of CD requires the demonstration of histological changes associated with the disease, which can be classifi ed according to Marsh, Marsh modifi ed (Oberhuber) , or the more recent, simplifi ed Corazza classifi cation ( 79 -81 ) ( Table 4) . Small-bowel biopsy is also useful for the diff erential diagnosis of malabsorptive disorders ( 82, 83 ) .
A recent guideline promulgated by the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) proposed that it may be possible to avoid any intestinal biopsy in children who meet the following criteria: characteristic symptoms of CD, TTG IgA levels > 10 × upper limit of normal (confi rmed with a positive EMA in a diff erent blood sample), and positive HLA-DQ2 ( 84 ) . A TTG antibody IgA > 5 × upper limit of normal was observed in 9 % of 236 adult patients with suspected CD and had a PPV for CD of 86.4 % ( 85 ). PPV was 97.4 % among 150 symptomatic children who met the " triple test " ESPGHAN criteria ( 86 ) . Among 3,031 family members (25 % younger than 18 years old) of patients with CD, TTG antibody IgA was abnormal in 336 (11 % ); of these, 88 (26 % ) had TTG antibody IgA ≥ 100 U ( 87 ). Population-based data are not available to know how frequent the " triple test " criteria are met by unselected populations. In the absence of standardization of TTG assays, use of a predefi ned threshold to select a population to avoid intestinal biopsy may not be the optimal strategy ( 88 ) . Prospective data to validate ESPGHAN recommendation in children or adults are lacking.
Histological abnormalities associated with CD can be patchy ( 89 -93 ) . Multiple biopsies of duodenum should be performed if the diagnosis of CD is considered. Among 132,352 patients without known CD who underwent duodenal biopsy in the United States, the probability of a new diagnosis of CD was signifi cantly increased when ≥ 4 specimens were submitted (1.8 % vs. 0.7 % , P < 0.0001) ( 94 ) . Unfortunately, four or more biopsies were taken in only 39 % of patients undergoing biopsy for evaluation of malabsorption / suspicion of CD ( 94 ) . Th e rate of duodenal biopsy was signifi cantly lower among black, older (70 years and older), and male patients ( 95 ) . In children and adults with positive CDspecifi c serologies, adding biopsies of the duodenal bulb increases the diagnostic yield because 9 -13 % had villous atrophy exclusively in the bulb ( 96 -98 ) . A targeted duodenal bulb biopsy from either the 9-or the 12-o ' clock position in addition to biopsies of Summary of the evidence . Th e most important genetic risk factor for CD is the presence of HLA-DQ heterodimers DQ2 (encoded by alleles A1 * 05 and B1 * 02) and DQ8 (encoded by alleles A1 * 03 and B1 * 0302) ( 108 -110 ) . In a prospective study that included 463 symptomatic patients referred for small-bowel biopsy due to suspicion of CD, the addition of HLA-DQ typing to serological tests (TTG and EMA) did not improve the accuracy of serologic tests alone for diagnosis of CD ( 78 ) . HLA-DQ2 ( ~ 95 % ) or HLA-DQ8 ( ~ 5 % ) are present in almost all patients with CD ( 111,112 ). Testing negative for both HLA-DQ types makes CD diagnosis very unlikely (NPV > 99 % ) ( 78 ) . Among rare patients not carrying these heterodimers, the majority encoded half of the HLA-DQ2 heterodimer ( 113 ) . Because HLA-DQ2 is present in approximately 25 -30 % of the white population ( 111, 114 ) , testing for CD with either HLA-DQ type is not useful because the PPV is only about 12 % ( 78 ).
HLA-DQ2 and -DQ8 testing has been useful for exclusion of CD in patients with either equivocal small-bowel histological fi nding or those following a GFD ( 74 ) . HLA-DQ2 and -DQ8 testing has been used to exclude a diagnosis of CD in patients with unexplained sprue ( 115, 116 ) . Th e prevalence of CD among persons aff ected by Down ' s syndrome was 10 % in the United States ( 117 ) . HLA-DQ2 was present in 88 % of persons with both Down ' s syndrome and positive EMA, but only 16 % of those with Down ' s and negative EMA ( 117 ) . In a prospective study including 155 children with Down ' s syndrome, all children with CD tested positive for either HLA-DQ2 or -DQ8 ( 118 ). Testing negative for both HLA-DQ2 and -DQ8 can reassure most parents of children with Down ' s syndrome about the absence of genetic risk for CD development. Th e utility of HLA testing in other at-risk groups (such as Type I diabetics or family members) is more limited because a high proportion of these subjects carry the CD susceptibility alleles (e.g., 73 % of fi rst-degree family members carry HLA-DQ2) ( 16 ) .
Capsule endoscopy allows non-invasive visualization of the whole small-bowel mucosa ( 119 ) . Capsule endoscopy can be the distal duodenum has a sensitivity of 96 % for the diagnosis of CD ( 99 ) . Care must be taken when interpreting duodenal bulb biopsies to allow for the normal surface architectural changes that overlie Brunner ' s glands and the acute infl ammatory changes of peptic duodenitis. Expert opinion suggests that only a single biopsy specimen should be obtained with each pass of the biopsy forceps ( 5 ); however, there is no evidence that supports that recommendation. We recommend multiple biopsies of the duodenum including one or two biopsies of the bulb (either 9-or 12-o ' clock position) and at least four biopsies of post-bulbar duodenum. Th ere are insuffi cient data to guide practice in patients who have not yet been tested serologically or in whom the pre-test prevalence is much lower. Th e added yield of duodenal bulb biopsies is likely to be small in such circumstances.
Lymphocytic infi ltration ( ≥ 25 intraepithelial lymphocytes per 100 epithelial cells), also known as lymphocytic duodenosis, is common in the general population (prevalence of 5.4 % ) ( 100 ). Most patients with lymphocytic duodenosis do not belong to the spectrum of CD and other causes should be sought, including work-up to rule out CD ( 101, 102 ) . Th e frequency of diarrhea and weight loss was similar among patients with lymphocytic duodenosis and those with CD ( 102 ). Anemia, skin disorders, positive TTG, and HLA-DQ2 were more frequent among patients with CD ( 102 ). Other disorders have been associated with lymphocytic duodenosis, including Helicobacter pylori (H. pylori) infection, medications (e.g., non-steroidal anti-infl ammatory drugs), smallbowel bacterial overgrowth, and systemic autoimmune disorders ( 103 ) . Persistent intraepithelial lymphocytosis was observed in 56 % of patients with treated CD despite evidence of normal villous architecture; the only factor associated with this fi nding was oat consumption ( 104 ) .
Among 56 children without a prior diagnosis of CD and lymphocytic duodenosis evaluated at a referral center, CD was diagnosed in only 9 % of these cases ( 105 ) . GFD may be benefi cial in children and adults with either lymphocytic duodenosis or Marsh II lesions and positive EMA ( 106, 107 ) .
ROLE OF ANCILLARY TESTING IN CD
Recommendations
(1) HLA-DQ2 / DQ8 testing should not be used routinely in the initial diagnosis of CD. (Strong recommendation, moderate level of evidence) (2) HLA-DQ2 / DQ8 genotyping testing should be used to eff ectively rule out the disease in selected clinical situations. (Strong recommendation, moderate level of evidence) Examples of such clinical situations include but are not limited to: (3) (a) Equivocal small-bowel histological fi nding (Marsh I-II) in seronegative patients (b) Evaluation of patients on a GFD in whom no testing for CD was done before GFD (c) Patients with discrepant celiac-specifi c serology and histology performed in patients who are unable or unwilling to undergo upper endoscopy ( 120, 121 ) . A meta-analysis showed that capsule endoscopy had a pooled sensitivity of 89 % and specifi city of 95 % for diagnosis of CD ( 122 ) . Capsule endoscopy had better overall sensitivity for detection of macroscopic features of atrophy compared with regular upper endoscopy (92 % vs. 55 % ) ( 123 ) . Th e sensitivity of capsule endoscopy is less when there is partial villous atrophy and all non-atrophic lesions (Marsh I -II) may elude visual detection ( 123 ) . In addition, markers of villous atrophy were not observed by capsule endoscopy among eight patients with positive TTG or EMA and normal duodenal biopsy ( 124 ) . Capsule endoscopy can detect severe complications associated with CD ( 87,125 -127 ) . Extensive mucosal damage detected by capsule endoscopy was associated with low albumin and refractory CD Type II ( 125 ) . Macroscopic features of atrophy found in 31 % of the cases was the most frequent fi nding by capsule endoscopy in patients with non-responsive CD (NRCD) ( 127 ) . Other capsule fi ndings among patients with NRCD include stenosis, erosions, ulcers, and lymphoma ( 125, 127 ) . Erosions or ulcerations are frequent fi ndings among NRCD patients oft en associated with the use of non-steroidal anti-infl ammatory drugs ( 127 ) . Capsule fi ndings in complicated CD may be used to assess the need for further evaluation with deep enteroscopy, especially among patients with clinical suspicion of lymphoma, adenocarcinoma, or ulcerative jejunitis ( 128 ) . Other diagnostic modalities that may be of value in complicated CD include computed tomography enterography and magnetic resonance imaging enterography or enteroclysis ( 115, 129, 130 ) .
D -xylose is a pentose absorbed unchanged from the small bowel ( 131 ) . Th e D -xylose test involves measurement of serum xylose or measurement of excreted xylose in urine aft er ingestion of D -xylose ( 132 ) . Th e test is abnormal in patients with malabsorption due to mucosal disorders but remains normal in those with maldigestion of pancreatic origin ( 132 ) . Sensitivity ( < 65 % ) and specifi city ( < 74 % ) for either 1-h plasma test or 4-h urine excretion test are both lower than those obtained with IgA-TTG or IgA-EMA and the accuracy of the test is suboptimal for diagnosis of CD ( 133, 134 ) .
Intestinal permeability is altered in CD ( 135 ) . Although permeability tests (e.g., sucrose, lactulose-mannitol ratio) can detect the gross changes on intestinal permeability associated with CD, their sensitivity and specifi city are quite variable and these tests are not recommended for diagnosis of CD ( 136 -138 ) . Smallbowel follow-through does not have a role in the initial evaluation of patients with suspicion of CD and may have a limited role for evaluation of chronic diarrhea (e.g., suspicion of smallbowel diverticulosis) ( 139 ) . Jejunoileal fold pattern reversal had a sensitivity of 86 % for CD in a retrospective study ( 140 ) . Other radiological signs of malabsorption (e.g., dilation, fl occulation and segmentation of barium) are nonspecifi c (rarely seen with modern barium preparations) and can be seen in subjects with normal fecal fat analysis ( 141 ) . Salivary tests for detection of TTG antibodies are under active investigation but there is not enough evidence to make a recommendation for their use ( 142, 143 ) .
Th e sensitivity of fecal IgA antibodies against TTG was as low as 10 % , which is not suitable for accurate screening for CD ( 144 ) .
DIFFERENTIATION OF CD FROM NON-CELIAC GLUTEN SENSITIVITY
Recommendations
(1) Symptoms or symptom response to a GFD alone should not be used to diagnose CD, as these do not diff erentiate CD from non-celiac gluten sensitivity. (Strong recommendation, moderate level of evidence) (2) A diagnosis of non-celiac gluten sensitivity should be considered only aft er CD has been excluded with appropriate testing. (Strong recommendation, moderate level of evidence)
Summary of the evidence . Non-celiac gluten sensitivity, a condition in which individuals do not have the diagnostic features of CD but nonetheless develop celiac-like symptoms upon exposure to dietary gluten, is important to consider in the differential diagnosis of CD ( 70, 145, 146 ) . Symptoms alone cannot reliably diff erentiate CD from non-celiac gluten sensitivity as there is oft en substantial overlap in symptoms between the two conditions ( 70, 146 ) . Objective tests including celiac serology and small-intestinal histology (both obtained while the patient is consuming a gluten-rich diet) and HLA-DQ typing (to rule out CD if negative) are needed to diff erentiate between the two disorders ( 70, 146 ) . Knowledge of the pathogenesis, epidemiology, and natural history of non-celiac gluten sensitivity is quite rudimentary ( 142,146 -148 ) . However, at this time, it appears that non-celiac gluten sensitivity does not have a strong hereditary basis, is not associated with malabsorption or nutritional defi ciencies, and is not associated with any increased risk for auto-immune disorders or intestinal malignancy. Given these major diff erences in natural history and outcomes, the diff erentiation of CD and non-celiac gluten sensitivity is important for advising patients regarding the importance of ongoing disease monitoring, the required duration and strictness of adherence to the GFD, and for counseling and testing of family members.
DIAGNOSIS AMONG PATIENTS ON A GFD
Recommendations
(1) While standard diagnostic tests (specifi c serology and intestinal biopsy) have a high PPV for CD, they should not be relied upon to exclude CD in patients already adhering to a GFD. (Strong recommendation, high level of evidence) (2) HLA-DQ2 / DQ8 genotyping should be used to try to exclude CD prior to embarking on a formal gluten challenge. (Strong recommendation, high level of evidence) (3) CD should be diff erentiated from non-celiac gluten sensitivity in order to identify the risk for nutritional defi ciency Th e importance of diff erentiating CD from non-celiac gluten sensitivity is outlined above. If a patient is unwilling or unable to undergo testing to make this distinction, then their further management becomes less well-defi ned. Th e management of non-celiac gluten sensitivity is symptom-based, without data to elicit major concerns for a long-term sequel of inadequate therapy ( 146, 147 ) . Th e ongoing management of CD is more complex, as described elsewhere in this document. It is reasonable to manage patients with a moderate to high suspicion for (unproven) CD in a similar fashion to those with known CD. However, this approach will of necessity include unnecessary monitoring, therapy, and expense. Th erefore the patient should be aware of the ongoing availability of defi nitive testing should they so desire.
states, complications of CD, risk for CD and associated disorders in family members, and to infl uence the degree and duration of adherence to the GFD. (Conditional recommendation, moderate level of evidence) (4) Formal gluten challenge should be considered, where necessary, to diagnose or exclude CD in patients already adhering to a GFD. (Strong recommendation, high level of evidence) (5) Despite the disadvantages of neither confi rming nor excluding a diagnosis of CD, some patients will opt to continue on a strictly GFD without undergoing formal gluten challenge; such patients should be managed in a similar fashion to those with known CD. (Conditional recommendation, low level of evidence)
Summary of the evidence . Th e specifi c serologic and histologic features of CD do not normalize immediately upon the initiation of a GFD ( 8, 43, 149, 150 ) . If the duration of GFD has been brief (less than 1 month), serology and histology are oft en still abnormal and can be used to diagnose CD in patients already on GFD. Conversely, given that the degree of serologic and histologic abnormality varies substantially in untreated CD, some patients will quickly revert to normal on a GFD. Hence, normal serologic and histologic fi ndings on a GFD cannot be used to exclude CD defi nitively ( 8,43,149,150 ). As discussed above, the required genotypes, encoding HLA-DQ2 or -DQ8, are not infl uenced by diet and can be used to evaluate the likelihood of CD in patients either on a normal or on a GFD ( 8, 151 ) . HLA-DQ2 / DQ8 testing should be performed prior to embarking on a formal gluten challenge as a negative result will obviate the need for further workup.
Patients with CD treated by a strict GFD may yield negative results on celiac serology testing and small-intestinal histology ( 8, 43, 149, 151 ) . HLA-DQ2 or -DQ8 positivity will persist but is not suffi ciently specifi c to be useful for positive diagnosis ( 8 ) . Gluten challenge is the process whereby a patient with suspected but unproven CD and already treated with a GFD reverts to a normal, gluten-rich diet, under medical supervision, to enable diagnostic testing ( 152, 153 ) . Gluten challenge was routine for CD diagnosis in the past, but is now less frequently used because of the high PPV of specifi c celiac serology testing.
Gluten challenge remains the gold standard for CD diagnosis in HLA-DQ2 or -DQ8-positive patients who have normal serologic and histologic fi ndings when tested on a GFD. It must be noted that patients who develop severe symptoms following gluten ingestion are not suitable candidates for gluten challenge. Although gluten challenge with a diet containing at least 10 g of gluten per day for 6 -8 weeks has long been the norm, there are few data to indicate the diagnostic effi cacy of this approach or the optimum dose or duration of challenge ( 154, 155 ) . A recent study found that even if a patient can only tolerate lower doses of gluten (3 g per day), diagnostic changes are seen in most CD patients aft er as little as 2 weeks of gluten ingestion ( 152 ) . An approach to gluten challenge is presented in Figure 2 ( 152 ). Figure 2 . An approach to gluten challenge for the diagnosis or exclusion of celiac disease (CD) in patients maintained on a gluten-free diet without prior defi nitive diagnostic testing (adapted from Leffl er ( 152 )).
(1) Tissue transglutaminase, endomysium, and / or deamidated gliadin peptide antibody serology. (2) Normal or non-diagnostic histology in a patient with positive serology while maintaining a gluten-free diet (GFD) requires gluten challenge and repeat biopsy for defi nitive diagnosis or exclusion of CD. (3) Those with positive celiac serology but a normal biopsy have potential CD and should be evaluated and monitored further depending upon their clinical circumstances. (4) In one study of subjects receiving a gluten challenge for 14 days, Marsh III histology was seen in 68 % , positive celiac serology in 75 % , and either Marsh III histology or positive serology in 90 % . Thus, a 2-week gluten challenge may yield false-negative results in 10 % of patients. The added diagnostic sensitivity of extending the challenge to 8 weeks is unknown. (5) Celiac serology antibody concentrations may continue to rise after a gluten challenge ends. In one study positive tissue transglutaminase serology was seen in 25 % of subjects and positive deamidated gliadin peptide serology in 30 % at the end of a 14-day gluten challenge; 50 % had at least one positive serology on day 14. Positivity rates rose to 55 % and 45 % , respectively, 14 days later, despite the fact that subjects had resumed a GFD; 75 % had at least one positive serology on day 28, 14 days after the gluten challenge ended. HLA, human leukocyte antigen.
MANAGEMENT OF CD
Recommendations
(1) People with CD should adhere to a GFD for life. A GFD entails strict avoidance of all products containing the proteins from wheat, barley, and rye. (Strong recommendation, high level of evidence) (2) While pure oats appear to be safely tolerated by the majority of people with CD, oats should be introduced into the diet with caution and patients should be monitored closely for evidence of adverse reaction. Summary of the evidence . A GFD is the only eff ective treatment for CD as there are currently no medications that can reliably and safely prevent the mucosal damage caused by exposure to gluten. Th e principal sources of dietary gluten are wheat, barley, and rye. While the term " gluten free " implies complete elimination of all sources of gluten, in reality this is not possible due to contamination of foods with trace amounts of gluten. Hence the term " gluten free " indicates a diet that contains gluten at such a low level as to be considered harmless. Th e exact level below which gluten is harmless is not known, but a recent review suggests less than 10 mg per day is unlikely to cause damage in most patients ( 156 ) . Th e current international Codex Alimentarius defi nes gluten-free foods as having less than 20 p.p.m. of gluten. A GFD will result in resolution of symptoms and repair of the intestinal damage over time in most people with CD. Failure to adhere to the GFD carries risk for adverse health consequences and increased mortality. Th ere is an increased risk for malignancies (e.g., small-bowel adenocarcinoma, cancer of esophagus, B-cell and T-cell non-Hodgkin lymphomas), and in particular intestinal T-cell lymphomas, in people with CD ( 157 ) . Evidence suggests the risk for increased mortality and malignancies is reduced in those who adhere to the diet ( 158 -160 ) . Th ere is evidence that a GFD improves nutritional parameters in symptomatic adults and children with CD. Th is includes increases in body weight, body mass index, and bone mineralization ( 161 -163 ) .
Untreated CD is associated with an increased prevalence of low bone mineral density and risk for fractures. Treatment of CD with a GFD improves bone mineral density in both adults and children ( 45,164 -176 ) . Women with CD have an increased risk of infertility, spontaneous abortions, preterm deliveries, and delivery of low birth weight infants. Treatment of women with CD with GFD reduces these risks to that of the general population ( 177 -181 ) .
Consumption of oats improves the nutrient content of the diets of people on a GFD by increasing the intake of fi ber, vitamin B, magnesium, and iron ( 182 ) . While in the past there has been concern that oats can cause intestinal mucosal damage in people with CD, recent evidence suggests oats that are pure and uncontaminated by other gluten-containing grains can be safely ingested by most people with CD provided they are taken in limited quantities ( 183 -190 ) . However, there is still need for caution when introducing oats into the diet of people with CD as there is a high likelihood that commercial oats may be contaminated with gluten from other grains ( 191, 192 ) . Th ere is also evidence that a small number of people with CD may be intolerant to pure oats and can develop an immunological response to oat avenins. Based on in vitro studies, this may in part be related to a variation in toxicity of oat cultivars ( 193, 194 ) . Commercial oats should only be introduced into the diet of people with CD provided the oats are guaranteed to be pure and uncontaminated by other gluten-containing grains. Even if confi rmed to be pure, if oats are introduced into the diet of people with CD there should be careful follow-up to monitor for signs of both clinical and serological relapse.
Following a GFD can be cumbersome and strict avoidance of gluten is diffi cult because there are many hidden sources of gluten in commercial food products. Th ere is evidence that compliance with the GFD is improved in those who are more knowledgeable about CD and the diet ( 195 -197 ) . Most physicians do not have the knowledge about the diet to adequately counsel patients. Registered dietitians are trained to evaluate patients for potential current and future dietary nutrient defi ciencies and advise and educate them on how to maintain a strict GFD with provision of healthy alternatives to gluten. Th e Academy of Nutrition and Dietetics has published evidence-based guidelines for treatment of CD and it is recommended these are followed (available at http://www.adaevidencelibrary.com/topic.cfm?cat=3677 ). In addition to providing initial counseling and education, once the relationship with a dietitian is established the patient can be monitored for compliance with the diet and undergo repeated assessments for potential dietary nutrient defi ciencies, inadequate fi ber intake, and excess weight gain, each of which may be associated with adherence to the GFD.
Th ere is some evidence that people with untreated CD are more frequently defi cient in a number of micronutrients compared to those without CD. Micronutrient defi ciencies identifi ed include iron ( 198 -203 ) , folic acid ( 198, 204 ) , and vitamin B12 and B6 ( 205 -207 ) . Low bone mineral density in people with untreated CD is believed to be partly due to vitamin D defi ciency. Other defi ciencies described in CD include copper, zinc, and carnitine ( 199, 208, 209 ) . Some defi ciencies may persist even aft er a prolonged period on a GFD ( 210, 211 ) . In addition to testing for micronutrient defi ciencies, dietary review by a registered dietitian, both at the time of initial diagnosis and aft er starting a GFD, is helpful for identifying potential nutrient defi ciencies.
Summary of the evidence . Th ere is universal agreement on the necessity of long-term monitoring of patients with CD ( 212 ) . Th e number of patients with CD who receive follow-up is unknown. In the United States, follow-up appears to be suboptimal in practice ( 213 ) . A systematic review supports the role of strict adherence to the GFD to control symptoms, improve quality of life, and decrease the risk of complications ( 214 ) . Normal growth and development are achievable on a GFD and should be goals for monitoring children with CD ( 215 ) . Control of symptoms (if present), facilitation of adherence to GFD, and avoidance or early detection of complications should be the general goals of monitoring aft er diagnosis of CD ( Figure 3 ) .
It is not clear who should perform follow-up of patients with CD and at what frequency. In a survey of patients in the United Kingdom, the health-care practitioner preferred by patients for followup was a dietitian with a doctor available if needed ( 216 ) . In a population-based cohort of 122 patients from the Midwest in the United States, there were 314 follow-up visits over a period of 5 years. Of these visits, 175 (56 % ) were conducted with primary-care providers and 122 (39 % ) with gastroenterologists ( 213 ) . A nationwide study from Finland showed that medical follow-up by primary-care providers was eff ective (average adherence rate was 88 % ) ( 217 ) . Annual follow-up with serology (TTG IgA) was associated with increasing rate of seroconversion of the TTG anti body (99 % ) among 2,245 patients who underwent systematic follow-up ( 58 ) . Until more evidence is available, annual follow-up seems reasonable.
MONITORING OF CD
Recommendations
(1) People with CD should be monitored regularly for residual or new symptoms, adherence to GFD, and assessment for complications. In children, special attention to assure normal growth and development is recommended. Th ere is extensive evidence to support the central role of consultation with a dietitian in patients with NRCD or if gluten contamination is suspected ( 218, 219 ) . Th ere is no evidence to suggest that medical follow-up by a dietitian and a doctor together is better (or worse) in terms of outcome than follow-up done by either provider alone.
Th ere are several methods to assess adherence to GFD: visits with the doctor and / or dietitian, serology, biopsy of intestine, and structured surveys. Th e gold standard for monitoring adherence to GFD is consultation with a skilled dietitian ( 220 ) . All serologic markers associated with celiac autoimmunity are gluten-dependent. A decrease from baseline values is expected within months of strict adherence to the GFD ( 221, 222 ) . A gluten challenge produces increasing values of antibodies ( 222 ) . Lack of declining values and / or persistently positive serology 1 year aft er starting a GFD strongly suggest gluten contamination ( 219 ) . Persistently positive serology was seen in only 1 % of patients who underwent annual follow-up during a 5-year period ( 58 ). Serology is not accurate to detect lesser degrees of gluten contamination. Seroconversion aft er GFD does not necessarily imply healing of the intestine ( 73, 223, 224 ) . Th e only accurate method available to verify intestinal healing is biopsy. Structured short surveys have been explored as an alternative to dietitian consultation for quick assessment of adherence to the diet ( 225 -227 ) . More studies are needed to examine the role of survey instruments for assessment of adherence in practice.
Patients with persistent or recurrent symptoms despite GFD require additional work-up to investigate the presence of disorders commonly associated with NRCD (see " Evaluation of nonresponsive CD " for details) ( 228 ) . Observational experience from referral centers supports the role of upper endoscopy with intestinal biopsies for evaluation of NRCD ( 218, 219, 229 ) . Intestinal biopsies are the only way to document healing of the intestine. In adults, the intestine will oft en fail to heal despite negative serology and absence of symptoms ( 73, 224, 230 ) . Th is lack of healing may increase the risk of lymphoma, bone disease, and ultimately the development of refractory CD ( 73, 231 ) . A large Swedish study demonstrated no risk of lymphoma (hazard ratio (HR) = 0.97; 95 % CI = 0.44 -2.14) among patients with normal histology, suggesting that mucosal healing could be the goal to consider during follow-up ( 232 ) . Among a group of 381 patients with baseline and follow-up biopsy aft er GFD, mucosal healing was associated with a borderline lower risk of death (HR = 0.13; 95 % CI: 0.02 -1.06; P = 0.06) adjusted for age and sex ( 73 ) . A much larger study from Sweden failed to confi rm a protective role of mucosal healing on mortality risk, yet mortality risk was significantly lower among patients who underwent follow-up biopsy ( 233 ) . Follow-up biopsy could be considered for assessment of mucosal healing in adults with negative serology and absence of symptoms. In a US study, the median time from onset of GFD to achieve mucosal healing was 3 years ( 73 ) . It is reasonable to do a follow-up biopsy in adults aft er 2 years of starting a GFD to assess for mucosal healing. Mucosal healing was observed in 95 % of children within 2 years of starting a GFD ( 230 ) . Follow-up biopsy is not recommended as a routine in children, although the evidence for mucosal healing aft er GFD in children is limited.
A signifi cant decrease (or normalization) of markers of malabsorption, such as fat content of the stools, should be expected aft er GFD ( 215 ) . Verifi cation of either declining antibody levels or seroconversion of CD-specifi c antibodies is critical during monitoring follow-up ( 221 ) . A persistently positive TTG antibody aft er GFD was signifi cantly associated with abnormal duodenal histology, low ferritin, and poor adherence to GFD ( 234 ) . Among a heterogenous group of patients with refractory iron-defi ciency anemia, anemia improved in 92 % of patients with CD aft er treatment with a GFD ( 235 ) . Copper defi ciency has been described in association with CD ( 208, 236 ) . Copper levels normalize within a month of adequate supplementation and a GFD, although reversibility of established neurological manifestations is unclear ( 208 ) . Copper defi ciency appears to be a very rare cause of peripheral neuropathy ( 237 ) . Long-term adherence to GFD leads to signifi cant improvement in bone density, especially among patients with strict adherence to the diet ( 238 ) . Although it is well accepted that CD is associated with an increased risk of bone fractures ( 239 -241 ) , the protective role of GFD on subsequent fracture risk may not be universal. Low serum vitamin B12 was present in about 12 % of patients with CD; correction should be expected with adequate replacement and GFD ( 205 ) .
NON-RESPONSIVE OR REFRACTORY CD
Recommendations
( Summary of the evidence . NRCD may be defi ned as persistent symptoms, signs or laboratory abnormalities typical of CD despite 6 -12 months of dietary gluten avoidance ( 218, 219, 242, 243 ) . NRCD is common, aff ecting from 7 to 30 % of patients treated with a GFD for CD ( 218, 219, 242 ) . Th ere are many distinct etiologies, including inadvertent gluten ingestion (the most common cause), other food intolerances (including lactose and fructose the initial diagnosis of CD by review of small-intestinal histology and serology obtained at the time of diagnosis ( Figure 4 ) . If the diagnosis of CD is not correct then response to a GFD is not to be expected and alternative diagnoses and treatments must be considered ( 248 ) . In those with confi rmed CD the ingestion of intolerance), small-intestinal bacterial overgrowth, microscopic colitis, pancreatic insuffi ciency, irritable bowel syndrome and refractory CD ( 218,219,242 -247 ) . Th us, careful evaluation is needed to identify and treat the specifi c source in any given patient ( 218, 219, 242, 243 ) . Th e fi rst step in evaluation is to re-confi rm gluten, either purposeful or inadvertent, is the most common cause of NRCD, being identifi ed in 35 -50 % of cases ( 218, 219 ) . Th us, a careful evaluation of the patient ' s diet by a dietitian who is experienced in CD management is the next important assessment. Th is evaluation should also seek other food intolerances, for example, to lactose or fructose. Celiac serologies are helpful if positive, as this points to probable gluten exposure as the cause for NRCD ( 218 ) . However, normal serologies do not exclude intermittent or low-level gluten ingestion suffi cient to cause persistent CD activity. Once dietary causes of NRCD have been excluded, small-intestinal biopsy should be repeated and the fi ndings compared to the diagnostic biopsy. Ongoing infl ammatory enteropathy with villous atrophy is consistent with refractory CD, gluten exposure, or possibly small-intestinal bacterial overgrowth and other causes of villous atrophy ( 115, 219, 242, 245 ) . Normal or nearnormal small-intestinal histology suggests other etiologies such as irritable bowel syndrome, microscopic colitis, food intolerances, or pancreatic insuffi ciency ( 218, 219, 242 ) . CD and microscopic colitis do overlap ( 249, 250 ) . Th ere are no suffi cient data to make a recommendation for routine testing of CD in patients with microscopic colitis. However, CD should be considered in patients with unresponsive microscopic colitis or those with microscopic colitis and other symptoms or signs suggestive of CD ( 251 ) .
Refractory CD (RCD) may be defi ned as persistent or recurrent symptoms and signs of malabsorption with small-intestinal villous atrophy despite a strict GFD for more than 12 months and in the absence of other disorders including overt lymphoma ( 145, 218, 252 ) . RCD is uncommon, aff ecting 1 -2 % of patients with CD ( 115, 244, 245 ) . In Type I RCD, lymphocyte infi ltration of the small-intestinal mucosa is similar to that seen in untreated CD ( 244, 246, 253, 254 ) . In Type II RCD, CD3-positive intraepithelial T cells exhibit an abnormal immunophenotype with lack of expression of normal cell surface diff erentiation markers such as CD8 ( 246, 253, 254 ) . Furthermore, T-cell receptor analyses may reveal oligoclonal T-cell expansion within the small-bowel mucosa ( 244, 246, 253, 254 ) . Th ese T-cell abnormalities in Type II RCD are associated with a signifi cantly less favorable prognosis as compared to Type I RCD ( 244, 246 ) . In the United States, Type I RCD appears to be more common than Type II RCD ( 245 ) .
Management of Type I RCD includes excluding inadvertent gluten exposure as a cause of ongoing disease activity and evaluation for and treatment of nutritional defi ciencies that may result from enteropathy with malabsorption ( 115, 218, 245 ) . Symptomatic treatment to reduce diarrhea is oft en required. Th ere are no published randomized, controlled trials of therapy for Type I RCD. Traditional medical treatment in severe cases consists of systemic steroid therapy with prednisone or a similar agent. In patients with an incomplete response to steroid treatment or who recur when the steroid dose is reduced, immunosuppressive agents such as azathioprine can be used. Recent reports indicate that budesonide or small-intestinal release mesalamine may be eff ective and carry the potential advantage of causing fewer side eff ects ( 255 -257 ) .
Th e general approach to management of Type II RCD is the same as for Type I RCD ( 115,244 -246 ) . However, symptoms and signs of disease are more severe in Type II RCD and are less likely to respond to therapy. Malnutrition in Type II RCD may be profound and require parenteral nutritional support. In one study, the 5-year survival of patients with Type II RCD was 44 % compared to 93 % for Type I RCD ( 244 ) . Causes of death included lymphoma, malnutrition, and sepsis.
Th ere are no published randomized, controlled trials of therapy for Type II RCD and there are no treatments of proven effi cacy. Agents that are used for treatment include systemic corticosteroids, enteric-coated budesonide, azathioprine or 6-mercaptopurine, methotrexate, cyclosporine, anti-TNF antibodies, or cladribine ( 6,115,116,244,252,255,258 -261 ) . Transformation to enteropathy-associated T-cell lymphoma (EATCL) is a prominent risk and may require treatment by surgery, chemotherapy, or bone marrow transplantation ( 262, 263 ) . In some patients EATCL may run a prolonged, non-aggressive course but the overall prognosis remains poor. (a) Equivocal small-bowel histological fi nding (Marsh I-II) in seronegative patients (b) Evaluation of patients on a GFD in whom no testing for CD was done before GFD , and served as consultant to Ironwood ( < $ 10,000), Flamentera ( < $ 10,000), Actogenix ( < $ 10,000), Bayer Healthcare Pharmaceuticals ( < $ 10,000), Vysera Biomedical ( < $ 10,000), 2G Pharma ( < $ 10,000), ImmunosanT ( < $ 10,000), and Shire US ( < $ 10,000). 
SUMMARY OF RECOMMENDATIONS
